We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
For manufacturers and distributors of intermediate and final feedingstuffs containing a medicinal premix or specified feed additives.
How we evaluated pre-exposure prophylactic (preventative) treatments for COVID-19.
Guidance for the pharmaceutical industry on Marketing Authorisations for veterinary medicines in the UK.
How a marketing authorisation holder should report a defect with a veterinary medicine.
The new presentation of Mounjaro gives four doses for once-a-week treatment over a month.
There have been very rare reports of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS) with pseudoephedrine.
A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices.
Documents relating to the new meningococcal B (MenB) vaccination (Bexsero®) programme starting from 1 September 2015.
Covering thalidomide, lenalidomide, and pomalidomide: temporary guidance for pregnancy prevention arrangements for patients taking them during COVID-19
Information for healthcare professionals and the public about the Pfizer/BioNTech's bivalent vaccines
Horse product from the USA seized at East Midlands Airport.
The CMA investigated the anticipated acquisition by Theramex HQ UK Limited of the European Rights to Viatris’ Femoston and Duphaston Products.
Information on good laboratory, manufacturing and distribution practice, good pharmacovigilance practice (GPvP), out-of-specification investigations, inspection metrics and fees.
Launched in January 2024, IRP aims to further help bring life-saving new medicines to UK patients without delay
How the MHRA makes decisions on what is a medicinal product (borderline products).
The MHRA has reviewed the latest evidence relating to the very rare risk of PRES and RCVS associated with medicines containing pseudoephedrine
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).